Preformulation designed to enable discovery and assess developability

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 2, 2010, Pages 90-100

  Hageman, Michael J ^a  

^a BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Absorption; Formulation; High throughput screening; Lipophilicity; Pharmacokinetics; Preformulation; Solubility; Solubilization; Stability

Indexed keywords

SURFACTANT;

DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HIGH THROUGHPUT SCREENING; IONIZATION; LIPOPHILICITY; PARTICLE SIZE; PH MEASUREMENT; PHYSICAL CHEMISTRY; PREFORMULATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; SUSPENSION;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 77949863841     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710790596781     Document Type: Review

References (68)

1. Kennedy, T. Managing the Drug discovery/development interface. Drug Discov. Today, 1997, 2, 436-444.
2. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods, 2000, 44, 235-249.
3. Kola, I.; Landis, J. Opinion: can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3, 711-716.
4. Borchardt, R.T.; Kerns, E.H.; Lipinski, C.A.; Thakker, D.R.; Wang, B. Pharmaceutical Profiling in Drug Discovery for Lead Selection, Springer/AAPS Press, New York, 2004.
5. Oprea, T.I. Current trends in lead discovery: are we looking for the appropriate properties? J. Comput. Aided Mol. Des., 2002, 16, 325-334.
6. Oprea, T.I.; Davis, A.M.; Teague, S.J.; Leeson, P.D. Is there a difference between leads and drugs? a historical perspective. J. Chem. Inf. Comput. Sci., 2001, 41, 1308-1315.
7. Rishton, G.M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov. Today, 2003, 8, 86-96.
8. Hann, M.M.; Oprea, T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol., 2004, 8, 255-263.
9. Hageman, M.J. In: Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Borchardt, R.T.; Kerns, E.H.; Hageman, M.J.; Thakker, D.R.; Stevens, J.L. Eds.; Springer: NY, NY, 2006, pp. 99-130.
10. Keseru G.M.; Makara G.M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discov., 2009, 8, 203-212.
11. Testa, B.; Van de Waterbeemd, H.; Folkers, G.; Guy, R. Phamacokinetics Optimization in Drug Research: Biological, Physiological and Computational Strategies, Verlag Helvetica Chimica Acta, Zurich, 2001.
12. Yalkowsky S.H. Solubility and Solubilization in Aqueous Media, Oxford Univ Press, New York, 1999.
13. Gulyaeva, N.; Zaslavsky, A.; Lechner, P.; Chlenov, M.; McConnell, O.; Chait, A.; Kipnis, V.; Zaslavsky, B. Relative hydrophobicity and lipophilicity of drugs measured by aqueous two-phase partitioning, octanol-buffer partitioning and HPLC. A simple model for predicting blood-brain distribution. Eur. J. Medicinal Chem., 2003, 38, 391-396.
14. Yamagami, C.; Kawase, K.; Iwaki, K. Hydrophobicity parameters determined by reversed-phase liquid chromatography. XV: optimal conditions for prediction of log P(oct) by using RP-HPLC procedures. Chem. Pharm. Bull., 2002, 50, 1578-1583.
15. Kaliszan, R.; Wiczling, P. Theoretical opportunities and actual limitations of pH gradient HPLC. Anal. Bioanal. Chem., 2005, 382, 718-727.
16. Volgyi, G.; Ruiz, R.; Box, K.; Comer, J.; Bosch, E.; Takacs-Novak, K. Potentiometric and spectrophotometric pKa determination of water-insoluble compounds: validation study in a new cosolvent system. Anal. Chim. Acta., 2007, 583, 418-428.
17. Jia, Z.; Ramstad, T.; Zhong, M. Medium-throughput pKa screening pharmaceuticals by pressure-assisted capillary electrophoresis. Electrophoresis, 2001, 22, 1112-1118.
18. Ishihama, Y.; Nakamura, M.; Miwa, T.; Kajima, T.; Asakawa, N. A rapid method for pKa determination of drugs using pressure-assisted capillary electrophoresis with photodiode array detection in drug discovery. J. Pharm. Sci., 2002, 91, 933-942.
19. Poole, S.K.; Patel, S.; Dehring, K.; Workman, H.; Dong, J. Estimation of octanol-water partition coefficients for neutral and weakly acidic compounds by microemulsion electrokinetic chromatography using dynamically coated capillary columns. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2003, 793, 265-274.
20. Serajuddin, A.T.M. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev., 2007, 59, 603-616.
21. Stahl, P.H.; Wermuth, C.G. Handbook of Pharmaceutical Salt Properties, Selection, and Use Verlag Helvetica Chimica Acta and Wiley-VCH, Zurich and Weinheim, 2002.
22. Martin, A.N.; Swarbrick, J.; Cammarata, A. Physical Pharmacy, Lea & Febiger, Philadelphia, 969, pp. 301.
23. Hancock, B.C.; Zografi, G. Characteristics and Significance of the Amorphous State in Pharmaceutical Systems. J. Pharm. Sci., 1997, 86, 1-12.
24. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev., 2001, 46, 3-26.
25. Zhou, L.; Yang, L.; Tilton, S.; Wang, J. Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery. J. Pharm. Sci., 2007, 96, 3052-3071.
26. Guo, J.; Elzinga, P.A.; Hageman, M.J.; Herron, J.N. Rapid throughput solubility screening method for BCS class II drugs in animal GI fluids and simulated human GI fluids using a 96-well format. J. Pharm. Sci., 2008, 97, 1427-1442.
27. Kerns, E.H.; Di, L. Pharmaceutical profiling in drug discovery. Drug Discov. Today, 2003, 8, 316-323.
28. Chen, X.Q.; Antman, M.D.; Gesenberg, C.; Gudmundsson, O.S. Discovery pharmaceutics--challenges and opportunities. AAPS J., 2006, 8, E402-E408.
29. ten Tije, A.J.; Verweij, J.; Loos, W.J.; Sparreboom, A. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. Clin. Pharmacokinet., 2003, 42, 665-685.
30. Takashima, K.; Mizukawa, Y.; Morishita, K.; Okuyama, M.; Kasahara, T.; Toritsuka, N.; Miyagishima, T.; Nagao, T.; Urushidani, T. Effect of the difference in vehicles on gene expression in the rat liver--analysis of the control data in the Toxicogenomics Project Database. Life Sci., 2006, 78, 2787-2796.
31. Saha, P.; Kou, J.H. Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. Eur. J. Pharm. Biopharm., 2000, 50, 403-411.
32. Rege, B.D.; Kao, J.P.; Polli, J.E. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci., 2002, 16, 237-246.
33. Collnot, E.M.; Baldes, C.; Wempe, M.F.; Kappl, R.; Huttermann, J.; Hyatt, J.A.; Edgar, K.J.; Schaefer, U.F.; Lehr, C.M. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol. Pharm., 2007, 4, 465-474.
34. Beckwith-Hall, B.M.; Holmes, E.; Lindon, J.C.; Gounarides, J.; Vickers, A., Shapiro, M.; Nicholson, J.K. NMR-based metabonomic studies on the biochemical effects of commonly used drug carrier vehicles in the rat. Chem. Res. Toxicol., 2002, 15, 1136-1141.
35. Pestel, S.; Martin, H.J.; Maier, G.M.; Guth, B. Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats. J. Pharmacol. Toxicol. Methods, 2006, 54, 200-214.
36. Schulze, J.D.R.; Waddington, W.A.; Ell, P.J.; Parsons, G.E.; Coffin, M.D.; Basit, A.W. Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption. Pharm. Res., 2003, 20, 1984-1988.
37. Schulze, J.D.; Peters, E.E.; Vickers, A.W.; Staton, J.S.; Coffin, M.D.; Parsons, G.E.; Basit, A.W. Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. Int. J. Pharm., 2005, 300, 67-75.
38. Rohrs, B.R. In: Optimizing the "drug-like" properties of leads in drug discovery; Borchardt, R.T.; Kerns, E.H.; Hageman, M.J.; Thakker, D.R.; Stevens, J.L., Eds.; Springer: NY, NY, 2006, pp. 151-166.
39. Johnson, K.C.; Swindell, A.C. Guidance in the Setting of drug particle size specification to minimize variability in absorption. Pharm. Res., 1996, 13, 1795-1798.
40. Shudo, J.; Pongpeerapat, A.; Wanawongthai, C.; Moribe, K.; Yamamoto, K. In vivo assessment of oral administration of probucol nanoparticles in rats. Biol. Pharm. Bull., 2008, 31, 321-325.
41. Jindal, K.C.; Chaudhary, R.S.; Singal, A.K.; Gangwal, S.S.; Khanna, S. Effect of particle size on the bioavailability and dissolution rate of rifampicin. Indian Drugs., 1995, 32, 100-107.
42. Serajuddin, A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci., 1999, 88, 1058-1066.
43. Leuner, C.; Dressman, J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm., 2000, 50, 47-60.
44. Wong, J.; Brugger, A.; Khare, A.; Chaubal, M.; Papadopoulos, P.; Rabinow, B.; Kipp, J.; Ning, J. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev., 2008, 60, 939-954.
45. Higuchi, T. Chemical analysis of the percutaneous absorption process. J. Soc. Cosmetic Chemists., 1960, 11, 85-97.
46. Pellet, M.A.; Davis, A.F.; Hadgraft, J. of supersaturation on membrane transport: 2. piroxicam. Int. J. Pharm., 1994, 111, 1-6.
47. Megrab, N.A.; Williams, A.C.; Barry, B.W. Oestradiol permeation through human skin silastic membrane: effects of propylene glycol and supersaturation. J. Control Release, 1995, 36, 277-294.
48. Pellet, M.A.; Castellano, S.; Hadgraft, J.; Davis, A.F. The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro. J. Control Release, 1997, 46, 205-214.
49. Iervolino, M.; Raghavan, R.L.; Hadgraft, J. Membrane penetration enhancement of ibuprofen using supersaturation. Int. J. Pharm., 2000, 198, 229-238.
50. Mithani, S.D.; Bakatselou, V.; TenHoor, C.N.; Dressman, J.B. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm. Res., 1996, 13, 163-167.
51. Nerurkar, M.M.; Burton, P.S.; Borchardt, R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res., 1996, 13, 528-534.
52. Poelma, F.G.J.; Breas, R.; Tukker, J.J. Intestinal Absorption of Drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat. Pharm. Res., 1990, 7, 392-397.
53. Pouton, C.W. Formulations of self-emulsifying drug delivery systems. Adv. Drug Delev. Rev., 1997, 25, 47-48.
54. Humberstone, A.J.; Charman, W.N. Lipid-based vehicles for oral delivery of poorly soluble drugs. Adv. Drug Deliv. Rev., 1997, 25, 103-128.
55. Charman, W.N. Lipids, Lipophilic drugs and oral drug delivery - some emerging concepts. J. Pharm. Sci., 2000, 89, 967-978.
56. Bagwe, R.P.; Kanicky, J.R.; Palla, B.J.; Patanjali, P.K.; Shah, D.O. Improved drug delivery using microemulsions: rationale, recent progress, and new horizons. Crit. Rev. Ther. Drug Carrier Syst., 2001, 18, 77-140.
57. Hauss, D.J. Oral lipid-based formulations. Adv. Drug Deliv. Rev., 2007, 59, 667-676.
58. Collins-Gold, L.C.; Lyons, R.T.; Bartholow, L.C. Parenteral emulsions for drug delivery. Adv. Drug Deliv. Rev., 1990, 5, 189-208.
59. Benita, S.; Levy, M.Y. Submicron emulsions as colloidal carriers for intravenous administration: comprehensive physicochemical characterization. J. Pharm. Sci., 1993, 82, 1069-1079.
60. Ranson, M.; Howell, A.; Cheeseman, S.; Margison, J. Liposomal drug delivery. Cancer Treat. Rev., 1996, 22, 365-379.
61. Wang, Y.; Mesfin, G.M.; Rodriguez, C.A.; Slatter, J.G.; Schuette, M.R.; Cory, A.L.; Higgins, M.J. Venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats following intravenous administration of a novel supersaturated submicron lipid emulsion. Pharm. Res., 1999, 16, 930-938.
62. Klang, S.H.; Parnas, M.; Benita, S. In: Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs; Muller, R.H.; Benita, S.; Bohm, B.H.L. Eds.; Medpharm Publ., Stuttgart, Germany, 1998; pp. 31-65.
63. Gao, P.; Rush, R.D.; Pfund, W.P.; Huang, T.; Bauer, J.M.; Morozowich, W.; Kuo, M.T.; Hageman, M.J. Development of a supersaturatable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci., 2003, 92, 2395-2407.
64. Gao, P.; Guyton, M.E.; Huang, T.; Bauer, J.M.; Stefanski, K.J.; Lu, Q. . Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev. Ind. Pharm., 2004, 30, 221-229.
65. Gao, P.; Morozowich, W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert Opin. Drug Deliv., 2006, 3, 97-110.
66. Thompson, D.O. Cyclodextrins -enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst., 1997, 14, 1-104.
67. Rajewski, R.A.; Stella, V.J. Pharmaceutical applications of cyclodextrins. 2. in vivo drug delivery. J. Pharm. Sci., 1996, 85, 1142.
68. Cho, M.J.; Chen, F.J.; Huczek, D.L. Effects of inclusion complexation on the transepithelial transport of a lipophilic substance in vitro. Pharm. Res., 1995, 12, 560-564.